These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38282187)

  • 1. Fanconi Anemia Complementary Group A (FANCA) Facilitates the Occurrence and Progression of Liver Hepatocellular Carcinoma.
    Huang FD; Zhong YP; Sun GY; Xu QJ; Xing ZY; Chen KH; Liao LS; Dong MY
    Dig Dis Sci; 2024 Mar; 69(3):1035-1054. PubMed ID: 38282187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
    Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
    Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
    Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
    J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the implication of steroid 5 alpha-reductase 3 on prognosis and immune microenvironment in Liver Hepatocellular Carcinoma.
    Lu Y; Liu Z; Zheng Y; Liu X; Liu X; Chen N; Mao K; Lin W
    Ann Med; 2024 Dec; 56(1):2408463. PubMed ID: 39340288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Kang Y; Zhong R; Gan Y; You J; Chen J; Chen F; Chen L
    J Transl Med; 2024 Oct; 22(1):911. PubMed ID: 39375712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.
    He D; Zhang X; Tu J
    Cancer Med; 2020 Dec; 9(23):8782-8800. PubMed ID: 32978904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.
    Chen G; Mo S; Yuan D
    Biomed Res Int; 2021; 2021():9911784. PubMed ID: 34195286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer.
    Fan S; Zhang S; Kong D; Wang H; Shi Y; Wang Z; Zheng H
    Comb Chem High Throughput Screen; 2023; 26(7):1298-1310. PubMed ID: 36017842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
    Qin P; Huang H; Wang J; Jiang T; Zeng N; Wang Q; He Y; Zhou Y
    Med Oncol; 2023 Aug; 40(9):276. PubMed ID: 37612479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the diagnostic value, prognostic value, and biological functions of NPC gene family members in hepatocellular carcinoma based on a multi-omics analysis.
    Chen K; Zhang X; Peng H; Huang F; Sun G; Xu Q; Liao L; Xing Z; Zhong Y; Fang Z; Liao M; Luo S; Chen W; Dong M
    Funct Integr Genomics; 2023 Aug; 23(3):264. PubMed ID: 37541978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Validation of DEPDC1B as an Independent Early Diagnostic and Prognostic Biomarker in Liver Hepatocellular Carcinoma.
    Fan X; Wen J; Bao L; Gao F; Li Y; He D
    Front Genet; 2021; 12():681809. PubMed ID: 35095994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
    He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
    Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
    Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
    Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.